Marty Makary’s exit as head of the Food and Drug Administration is giving the biotech industry hope for stability after months of turmoil.
Industries Health Facebook X LinkedIn Email Link Gift Expand Marty Makary Photographer: Valerie Plesch/Bloomberg Facebook X LinkedIn Email Link Gift Gift this article Contact us: Provide news feedback or report an error Confidential tip?
Send a tip to our reporters Site feedback: Take our Survey New Window Facebook X LinkedIn Email Link Gift By Gerry Smith May 12, 2026 at 7:10 PM UTC Updated on May 12, 2026 at 7:47 PM UTC Bookmark Save Marty Makary ’s exit as head of the Food and Drug Administration is giving the biotech industry hope for stability after months of turmoil.
Makary’s departure , which was announced by President Donald Trump on Tuesday, ended his tumultuous time at the more than 16,000-person agency tasked with ensuring that Americans’ food and medicines are safe and effective. His appointment last year was initially viewed positively by biotech leaders who saw the surgeon from Johns Hopkins University School of Medicine as a less radical choice than others picked by Health Secretary Robert F. Kennedy Jr .
